120108-63-6

Usage

Uses

Used in Pharmaceutical Research and Development:
2-Chlorophenylalanine hydrochloride is used as a building block for the synthesis of novel drugs. Its unique structure allows for the exploration of halogen substitution effects on phenylalanine metabolism, which can lead to the discovery of new therapeutic agents.
Used in Mood Disorder Therapy:
2-Chlorophenylalanine hydrochloride is used as a potential therapy for conditions such as depression, anxiety, and other mood disorders. Its ability to modulate neurotransmitter levels in the brain makes it a promising candidate for the treatment of these conditions, offering new avenues for managing mental health issues.

Upstream product

• 5440-50-6 N-acetyl-3-(2-chlorophenyl)-2-ethoxycarbonyl alanine ethyl ester 

Downstream Products

• 1251948-98-7 7-chloro-3-(2-chlorobenzyl)-1-cyclopropyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione 
• 1059065-41-6 (E)-5,7-dichloro-3-(2-chlorobenzyl)-1-(4-methoxybenzyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059066-15-7 7-chloro-3-(2-chlorobenzyl)-1-(4-methoxybenzyl)-5-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059064-18-4 7-chloro-3-(2-chlorobenzyl)-5-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059065-40-5 7-chloro-3-(2-chlorobenzyl)-1-(4-methoxybenzyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione 
• 1276544-60-5 3-(2-chlorobenzyl)-7-fluoro-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione 
• 1276544-48-9 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-7-chloro-3-(2-chlorobenzyl)-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione 
• 1276544-46-7 2-(7-chloro-3-(2-chlorobenzyl)-2,5-dioxo-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepin-1-yl)ethyl acetate 
• 1276544-20-7 7-chloro-3-(2-chlorobenzyl)-5-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1276544-19-4 7-chloro-3-(2-chlorobenzyl)-1-(4-methoxybenzyl)-5-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1276544-44-5 7-chloro-3-(2-chlorobenzyl)-1-(2-hydroxyethyl)-5-(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1276544-50-3 5,7-dichloro-3-(2-chlorobenzyl)-1-(2-chloroethyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 856571-32-9 3-(2-chlorophenyl)-2-{2-[(1H-indole-2-carbonyl)amino]benzoylamino}propionic acid ethyl ester 
• 856571-13-6 2-(2-aminobenzoylamino)-3-(2-chlorophenyl)propionic acid ethyl ester 

Relevant academic research and scientific papers

Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"

In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.